Christine Lavery
Overview
Explore the profile of Christine Lavery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lavery C, Hendriksz C, Jones S
Orphanet J Rare Dis
. 2017 Oct;
12(1):168.
PMID: 29061114
Background: Sanfilippo syndrome (mucopolysaccharidosis type III; MPS III) is an inherited monogenic lysosomal storage disorder divided into subtypes A, B, C and D. Each subtype is characterized by deficiency of...
2.
Ghosh A, Shapiro E, Rust S, Delaney K, Parker S, Shaywitz A, et al.
Orphanet J Rare Dis
. 2017 Jun;
12(1):117.
PMID: 28651568
Background: Mucopolysaccharidosis type III is a progressive, neurodegenerative lysosomal storage disorder for which there is currently no effective therapy. Though numerous potential therapies are in development, there are several challenges...
3.
Bruni S, Lavery C, Broomfield A
Mol Genet Metab Rep
. 2016 Aug;
8:67-73.
PMID: 27536552
Unlabelled: Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal storage disease. Affected individuals have disease ranging from attenuated to severe with significant disease burden, disability, and premature death. Early...
4.
Biegstraaten M, Arngrimsson R, Barbey F, Boks L, Cecchi F, Deegan P, et al.
Orphanet J Rare Dis
. 2015 Apr;
10:36.
PMID: 25885911
Introduction: Fabry disease (FD) is a lysosomal storage disorder resulting in progressive nervous system, kidney and heart disease. Enzyme replacement therapy (ERT) may halt or attenuate disease progression. Since administration...
5.
Lavery C, Hendriksz C
JIMD Rep
. 2014 Apr;
15:59-66.
PMID: 24718838
Background: Morquio syndrome A (mucopolysaccharidosis type IVA) is an autosomal recessive, life-limiting lysosomal storage disease characterized by deficient activity of the enzyme galactosamine-6-sulfatase. The disease affects multiple body systems, and...
6.
Hendriksz C, Lavery C, Coker M, Ucar S, Jain M, Bell L, et al.
Orphanet J Rare Dis
. 2014 Mar;
9:32.
PMID: 24602160
Background: Morquio A syndrome (or mucopolysaccharidosis IVa) is an ultra-rare multi-organ disease, resulting in significantly impaired functional capacity, mobility and quality of life (QoL). Methods: This patient-reported outcomes survey evaluated...
7.
Moore D, Connock M, Wraith E, Lavery C
Orphanet J Rare Dis
. 2008 Sep;
3:24.
PMID: 18796143
Background: Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disease subdivided into three phenotypes of increasing severity: Scheie, Hurler-Scheie and Hurler. To gauge the effectiveness of treatments and...
8.